glp-1 agonist and heart failure Glucagon-like peptide 1 receptor agonists: cardiovascular benefits mechanisms of action Increased Risk of Heart Failure

Finally, some clinical case studies and short series suggest their benefits also in patients with CKD stage 5D, although it should be recalled that this indication is not included in the labeling of arGLP-1 s.114,115 The Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease (FLOW), a phase 3 clinical trial involving more than 3,000 patients with type 2 DM and moderate-severe CKD (eGFR 2575 ml/min/1.73 m2 and Urine Alb/Cr ratio of 3005,000 mg/g) is currently underway (NCT03819153)

FEBS letters , 104 (1), 119-22

La ecografa permite diagnosticar la esteatosis heptica, sin embargo existe una gran variabilidad interobservador a la hora de valorar su grado

This is an area where I see the highest level of need among my patients

This effect is dose-dependent and more common during the loading phase when daily doses are at their highest